Humana stock after recent weakness

Humana (HUM) has come under pressure recently, with the stock showing negative returns over the past month and past 3 months. That price move is prompting some investors to reassess the health insurer’s current valuation.

At a share price of US$193.94, Humana’s recent 30 day share price return of 29.49% and year to date share price return of 26.67% contrast with a 1 year total shareholder return of 28.32%. This suggests that recent weakness has added to longer term pressure on sentiment around its growth prospects and risk profile.

If you are reassessing Humana and want to broaden your watchlist in healthcare, it could be a good time to scan our curated list of 26 healthcare AI stocks as another area to research.

So with Humana trading at US$193.94, sitting on multi year share price declines and screens suggesting a potential intrinsic discount, is this weakness opening up value, or is the market already pricing in all the growth ahead?

Most Popular Narrative: 32.5% Undervalued

Humana’s most followed narrative puts fair value at about $287.38 per share versus the last close of $193.94, framing a sizeable implied discount at today’s price.

Humana is focusing on operational efficiency by increasing the use of AI in its contact centers to enhance customer interactions and reduce costs, likely impacting net margins. The company is making substantial efforts to improve clinical excellence, including medication adherence campaigns and member engagement through in home visits combined with virtual health, which is expected to enhance medical margins and member experience.

Want to see what kind of revenue path and margin reset need to sit behind that fair value line? The narrative spells out a specific earnings ramp and valuation multiple that have to come together for $287.38 to make sense. If you are weighing whether today’s price reflects that story yet, the full set of assumptions is worth a close read.

Result: Fair Value of $287.38 (UNDERVALUED)

However, there are still real pressure points, including Medicare Advantage Star ratings disputes and potential changes to ACA subsidies, that could challenge this underpriced story.

Build Your Own Humana Narrative

If you are not fully convinced by any single perspective on Humana and want to evaluate the numbers yourself, you can build a custom view in minutes with Do it your way.

A great starting point for your Humana research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Humana is on your radar, do not stop there. Use the screener to surface fresh ideas that fit your style before the crowd spots them.

• Target income first by scanning 14 dividend fortresses that may suit investors who want cash returns to play a steady role in their portfolios.
• Hunt for potential bargains with 53 high quality undervalued stocks that line up solid fundamentals with prices that may not fully reflect their financial profile.
• Prioritise resilience by checking 86 resilient stocks with low risk scores that our model flags as having relatively lower risk scores compared to many peers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.